These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36229663)

  • 41. Tebentafusp in first-line melanoma trials: An outperforming outlier.
    Olivier T; Prasad V
    Transl Oncol; 2022 Jun; 20():101408. PubMed ID: 35364557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
    PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
    Tarhini AA; Frankel P; Margolin KA; Christensen S; Ruel C; Shipe-Spotloe J; Gandara DR; Chen A; Kirkwood JM
    Clin Cancer Res; 2011 Oct; 17(20):6574-81. PubMed ID: 21880788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
    Piperno-Neumann S; Diallo A; Etienne-Grimaldi MC; Bidard FC; Rodrigues M; Plancher C; Mariani P; Cassoux N; Decaudin D; Asselain B; Servois V
    Oncologist; 2016 Mar; 21(3):281-2. PubMed ID: 26911405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
    Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA
    Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
    Gerard C; Shum B; Nathan P; Turajlic S
    Immunooncol Technol; 2023 Sep; 19():100386. PubMed ID: 37483658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients].
    Gaillard A; Matet A; Rodrigues M
    Bull Cancer; 2023 Jan; 110(1):9-10. PubMed ID: 36357199
    [No Abstract]   [Full Text] [Related]  

  • 49. A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma.
    Mattei J; Ballhausen A; Bassett R; Shephard M; Chattopadhyay C; Hudgens C; Tetzlaff M; Woodman S; Sato T; Patel SP
    Melanoma Res; 2020 Dec; 30(6):574-579. PubMed ID: 32976223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
    Steeb T; Wessely A; Ruzicka T; Heppt MV; Berking C
    Eur J Cancer; 2018 Nov; 103():41-51. PubMed ID: 30205280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
    Schmittel A; Schmidt-Hieber M; Martus P; Bechrakis NE; Schuster R; Siehl JM; Foerster MH; Thiel E; Keilholz U
    Ann Oncol; 2006 Dec; 17(12):1826-9. PubMed ID: 16971664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
    Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Uveal melanoma: In the era of new treatments.
    Wespiser M; Neidhardt E; Negrier S
    Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
    O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
    Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
    Pföhler C; Cree IA; Ugurel S; Kuwert C; Haass N; Neuber K; Hengge U; Corrie PG; Zutt M; Tilgen W; Reinhold U
    Anticancer Drugs; 2003 Jun; 14(5):337-40. PubMed ID: 12782938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    Pelster MS; Gruschkus SK; Bassett R; Gombos DS; Shephard M; Posada L; Glover MS; Simien R; Diab A; Hwu P; Carter BW; Patel SP
    J Clin Oncol; 2021 Feb; 39(6):599-607. PubMed ID: 33125309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metastatic uveal melanoma: biology and emerging treatments.
    Woodman SE
    Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
    Montazeri K; Pattanayak V; Sullivan RJ
    Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.